Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases.
Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.
Department of Pediatric Hematology and Oncology, The Queen Silvia's Hospital for Children, Rondvägen 10, 41685, Göteborg, Sweden. karin.mellgren@vgregion.se.
K
http://orcid.org/0000-0002-9424-3200
K
Mellgren
Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
A
A
Attarbaschi
Department of Pediatrics, Division of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
O
O
Abla
Department of Pediatrics, Division of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
S
S
Alexander
Department of Paediatric Haematology and Oncology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
S
S
Bomken
Department of Pediatric Oncology and Hematology, University Children's Hospital, Banska Bystrica, Slovakia.
E
E
Bubanska
Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
A
A
Chiang
Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary.
M
M
Csóka
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
A
A
Fedorova
Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
E
E
Kabickova
Clinic of Paediatrics Haemathology and Oncology, Medical University of Gdansk, Gdansk, Poland.
L
L
Kapuscinska-Kemblowska
Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
R
R
Kobayashi
Pediatric Oncology and Hematology, University Hospital, Brno, Czech Republic.
Z
Z
Krenova
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
F
F
Meyer-Wentrup
Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
N
N
Miakova
Pediatric Hematology and Oncology, University of Padova, Padova, Italy.
M
M
Pillon
Department of Pediatric Oncology, Hôpital des Enfants, Toulouse, France.
G
G
Plat
Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
A
A
Uyttebroeck
Pediatric Hematology and Oncology, Addbrooke's Hospital, Cambridge University Hospitals Foundation Trust, Cambridge, UK.
D
D
Williams
Bone Marrow Transplantation and Pediatric Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.
G
G
Wróbel
Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Aachen, Germany.
U
U
Kontny
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007391:International Cooperation; D016411:Lymphoma, T-Cell, Peripheral / Q000628:therapy*; D008297:Male; D017063:Outcome Assessment, Health Care / Q000379:methods*; D012074:Remission Induction; D012189:Retrospective Studies; D055815:Young Adult
Non-Hodgkin’s lymphoma; Peripheral T cell lymphoma; Prognosis; Subtypes